Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Paymen...(cessing at the facility continues as pla...),Health

Date:12/4/2008

cessing at the facility continues as planned and the product and production process are meeting expectations. Haemacure plans on achieving its first patient-in-the-clinic objective in the first half of 2009 and anticipates commercial launch of its fibrin sealant on the U.S. market in the first half of 2011, in line with previously announced guidance.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first half of calendar 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on the use of fibrin sealant in aesthetics, adhesion prevention, combination with biomaterials, drug delivery, regenerative medecine, skin graft fixation for burn injuries, and wound healing. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure is headquartered in Montreal, Canada and operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of
'/>"/>

SOURCE Haemacure Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
2. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
3. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
4. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
5. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
6. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
7. Haemacure Reports on Financing Progress and Second Quarter Results
8. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
9. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
10. Haemacure financing receives shareholder consent - Series B Warrants are amended
11. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008